There are controversial data regarding the impact of coagulation factor XIII A subunit (FXIII-A) Val34Leu polymorphism in the pathogeneric of coronary artery disease (CAD) and myocardial infarction (MI). Assuming this genetic factor is associated with the thrombotic process, we explored the role of FXIII-A Val34Leu in CAD and MI in a Chinese Han population. We recruited 195 consecutive patients with CAD confirmed by coronary angiography as well as a group of 203 controls. Factor XIII A Val34Leu polymorphism was determined through polymerase chain reaction—single strand conformational polymorphism (PCR-SSCP) analysis. We did not find the Leu/Leu genotype in patients with CAD or controls. No significant difference in Val34Leu gene polymorphism distribution was found between patients with CAD and the controls (P = .923). Subgroup analysis according to the history of MI showed the heterozygote Val/Leu genotype was associated with a significantly decreased risk of MI (P = .005; adjusted odds ratio [OR] = 1.75; 95% confidence interval [CI] = 1.28-2.25). Furthermore, our study displayed that the frequency of the Leu34 allele in a Chinese Han population was lower than that in Caucasian populations (2.5 vs 20.4%-28.3%). Our preliminary data indicate that the FXIII-A Leu34 allele may contribute to a protective effect against the development of MI. There is a low prevalence of the Leu34 allele in Han Chinese compared to Caucasians.
Xu G., Jin GD, Fu GS, et al. Polymorphisms in the genes for coagulation factor II, V, VII in patients undergoing coronary angiography. J Zhejiang Uni (Science). 2003;4(3):369-373.
2.
Mikkola H., Syrjala M., Rasi V., et al. Deficiency in the A-subunit of coagulation factor XIII: two novel point mutations demonstrate different effects on transcript levels. Blood. 1994;84(2):517-525.
3.
Balogh I., Szoke G., Karpati L., et al. Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia. Blood. 2000;96(7):2479-2486.
4.
Wartiovaara U., Mikkola H., Szôke G., et al. Effect of Val34Leu polymorphism on the activation of the coagulation factor XIII-A. Thromb Haemost . 2000;84(4):595-600.
5.
Ariens RA, Philippou H., Nagaswami C., Weisel JW, Lane DA, Grant PJThe factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood. 2000;96(3):988-995.
6.
Lim BC, Ariens RA, Carter AM, Weisel JW, Grant PJGenetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet. 2003;361(9367):1424-1431.
Polgar J., Hidasi V., Muszbek L.Non-proteolytic activation of cellular protransglutaminase (placenta macrophage factor XIII). Biochem J. 1990;267(2):557-560.
9.
Schwartz ML, Pizzo SV, Hill RL, McKee PAHuman factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and crosslinking of fibrinogen and fibrin . J Biol Chem. 1973;248(4):1395-1407.
10.
Rallidis LS , Politou M., Komporozos C., et al. Factor XIII Val34-Leu polymorphism and the risk of myocardial infarction under the age of 36 years. Thromb Haemost. 2008;99(6):1085-1089.
11.
Aleksic N., Ahn C., Wang YWFactor XIIIA Val34Leu polymorphism does not predict risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol. 2002;22(2):348-352.
12.
Cho KH, Kim BC, Kim MK, Shin BANo association of factor XIII Val34Leu polymorphism with primary intracerebral hemorrhage and healthy controls in Korean population. J Korean Med Sci. 2002;17(2):249-253.
13.
Suzuki K., Henke J., Iwata M., et al. Novel polymorphisms and haplotypes in the human coagulation factor XIII A-subunit gene. Hum Genet. 1996 ;98(4):393-395.
14.
Mona S., Anderson JL, Scarvelis D., Doucette SP, Gagnon F., Wells PSFactor XIII Val34Leu variant and the risk of myocardial infarction . Thromb Haemost. 2007;97(4):635-641.
15.
Kohler HP, Max H., Ossei-Gerning N., Carter A., Mikkola H., Grant PJAssociation of a common polymorphism in factor XIII gene with myocardial infarction . Thromb Haemost. 1998;79(1):8-13.
16.
Kangsadalampai S., Board PGThe Val34Leu polymorphism in the A subunit of coagulation actor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity . Blood. 1998;92(8):2766-2770.
17.
Franco RF, Pazin-Filho A., Tavella MH, Simoes MV, Marin-Neto JA, Zago MAFactor XIII val34leu and the risk of myocardial infarction. Haematologica. 2000;85(1):67-71.
18.
Butt C., Zheng H., Randell E., Robb D., Parfrey P., Xie YGCombined carrier status of prothrombin 20210A and factor XIII-A Leu34 alleles as a strong risk factor for myocardial infarction: evidence of a gene-gene interaction. Blood. 2003;101(8):3037-3041.
19.
Roldan V., Corral J., Marin F., et al. Role of factor XIII Val34Leu polymorphism in patients <45 years of age with acute myocardial infarction. Am J Cardiol . 2003;91(10):1242-1245.
20.
Reiner AP, Heckbert SR, Vos HL, et al. Genetic variants of coagulation factor XIII, postmenopausal estrogen therapy, and risk of nonfatal myocardial infarction. Blood. 2003;102(1):25-30.
21.
Doggen CJ, Reiner AP, Vos HL, Rosendaal FRTwo factor XIII gene polymorphisms associated with a structural and functional defect and the risk of myocardial infarction in men. J Thromb Haemost. 2003;1(9):2056-2058.
22.
Catto AJ, Kohler HP, Bannan S., Stickland M., Carter A., Grant PJFactor XIII Val 34 Leu a novel association with primary intracerebral hemorrhage . Stroke. 1998;29(4):813-816.
23.
Gemmati D., Serino ML, Ongaro A., et al. A common mutation in the gene for coagulation factor XIII-A (Val34Leu): a risk factor for primary intracerebral hemorrhage is protective against atherothrombotic diseases. Am J Hematol. 2001;67(3):183-188.
24.
He J., Gu D., Wu X., et al. Major cause of death among men and women in China. N Eng J Med. 2005;353(11):1124-1134.
25.
Rosamond W. , Flegal K., Friday G., et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115(5):e69-e171.
Vanhoutte D. , Heymans S.Factor XIII: the cement of the heart after myocardial infarction?Eur Heart J. 2008;29(4):427-428.
28.
Board PG, Webb GC, McKee J., Ichinose A. Localization of the coagulation factor XIII A subunit gene (F13A) to chromosome bands 6p24-p25. Cytogenet Cell Genet . 1988;48(1):25-27.
29.
Ichinose A. , Davie EWCharacterization of the gene for the a subunit of human factor XIII (plasma transglutaminase), a blood coagulation factor . Proc Natl Acad Sci U S A. 1988;85(16): 5829-5833.
30.
Weisberg LJ , Shiu DT, Greenberg CS, Kan YW, Shuman MALocalization of the gene for coagulation factor XIII a-chain to chromosome 6 and identification of sites of synthesis. J Clin Invest. 1987 ;79(2):649-652.
31.
Vokó Z., Bereczky Z., Katona E., Adány R., Muszbek L.Factor XIII Val34Leu variant protects against coronary artery disease. Thromb Haemost. 2007 ;97(3):458-463.
Choudhury I. , Marsh JDMyocardial infarction in young patients. Am J Med. 1999;107(3):254-261.
34.
Kardasz I., De Caterina R.Myocardial infarction with normal coronary arteries: a conundrum with multiple aetiologies and variable prognosis: an update. J Intern Med . 2007;261(4):330-348.
35.
Speidl WS, Nikfardjam M., Niessner A., et al. Premature compared with late onset of coronary artery disease: young patients show a severe defect in fibrinolytic response to venous occlusion . Blood Coagul Fibrinolysis. 2007;18(2):165-171.
36.
Maitland-van der Zee AH, Peters BJ, Lynch AI, et al. The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13) on the effectiveness of statins: the GenHAT study. Pharmacogenet Genomics. 2009;19(5):338-344.
37.
Nahrendorf M., Hu K., Frantz S., et al. Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodelling in mice with myocardial infarction. Circulation . 2006 ;113(9):1196-1202.
38.
Nahrendorf M., Aikawa E., Figueiredo JL, et al. Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodeling: implications for FXIII therapy and antithrombin use in myocardial infarction . Eur Heart J. 2008;29(4): 445-454. DOI:10.1093/eurheartj/ehm558.
39.
Nahrendorf M., Weissleder R., Ertl G.Does FXIII deficiency impair wound healing after myocardial infarction?PLoS One . 2006 ;1:e48.
40.
Kohler HP, Futers TS, Grant PJPrevalence of three common polymorphisms in the A-subunit gene of factor XIII in patients with coronary artery disease. Thromb Haemost. 1999;81(4):511-515.
41.
Gallivan L. , Markham AF, Anwar R.The Leu564 factor XIIIA variant results in significantly lower plasma factor XIII levels than the Pro564 variant. Thromb Haemost. 1999; 82(4):1368-1370.
42.
Komanasin N. , Futers TS, Ariens RAS, Grant PJA novel polymorphism in the factor XIII B subunit (His95Arg) relates to the dissociation of the A2B2 tetramer. Thromb Haemost. 1999; 82(suppl):38.
43.
Boekholdt SM , Sandhu MS, Wareham NJ, Luben R., Reitsma PH, Khaw KTFibrinogen plasma levels modify the association between the factor XIII Val34Leu variant and risk of coronary artery disease: the EPIC-Norfolk prospective population study . J Thromb Haemost . 2006;4(10):2204-2209.
44.
Kobbervig C. , Williams E.FXIII polymorphisms, fibrin clot structure and thrombotic risk. Biophys Chem. 2004;112(2-3):223-228.
45.
Kohler HP, Mansfield MW, Clark PS, Grant PJInteraction between insulin resistance and factor XIII Val34Leu in patients with coronary artery disease. Thromb Haemost. 1999;82(3):1202-1203.
